Analyst Price Target is $4.65
▲ +214.19% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adaptimmune Therapeutics in the last 3 months. The average price target is $4.65, with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a 214.19% upside from the last price of $1.48.
Current Consensus is
The current consensus among 3 polled investment analysts is to hold stock in Adaptimmune Therapeutics. This Hold consensus rating has held steady for over two years.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.